Candel Therapeutics (NASDAQ: CADL) — Perfil da empresa, notícias e dados financeiros
Candel Therapeutics develops oncolytic viral therapies targeting solid tumors, enhancing cancer treatments and patient outcomes.
Candel Therapeutics
Candel Therapeutics (NASDAQ:CADL) specializes in the development of oncolytic viral therapies, a pioneering approach aimed at harnessing the power of viruses to selectively attack and destroy cancer cells while stimulating a potent, systemic immune response against the cancer. The company's innovative pipeline is focused on addressing a wide range of solid tumor types through robust clinical programs. With ongoing projects aimed at enhancing the efficacy and safety of cancer treatments, Candel Therapeutics is committed to improving patient outcomes and advancing the field of immuno-oncology. Their objective is to revolutionize cancer therapy by developing treatments that offer a better quality of life and survival rates for patients battling cancer.
Resumo
Operações
Produtos e/ou serviços de Candel Therapeutics
- Oncolytic Virus Therapy - Specializes in the development of novel oncolytic viral therapies for cancer patients, leveraging viruses to selectively kill cancer cells.
- CAN-2409 (HSV-1) - An investigational gene-mediated cytotoxic immunotherapy using an engineered herpes simplex virus to treat high-grade gliomas, a type of brain cancer.
- Neoantigen Technology - Works on personalized cancer vaccine technologies aiming to train the immune system to target specific mutations in cancer cells.
- CAN-3110 (HSV-1) - A second-generation oncolytic virus engineered for increased selectivity and potency against cancer cells, particularly for glioblastoma.
- Immuno-Oncology Pipeline - Involves the development of various immunotherapies designed to activate the patient’s immune system against cancer.
- Clinical Trial Management - Offers comprehensive management of clinical trials for their cutting-edge cancer treatments, ensuring adherence to regulatory standards and patient safety.
equipe executiva do Candel Therapeutics
- Paul-Peter TakPresident, CEO & Director
- Charles SchochSenior VP, CFO, Treasurer & Secretary
- Francesca BaroneChief Scientific Officer
- Seshu TyagarajanChief Technical & Development Officer
- Theodore JenkinsVice President of Investor Relations & Business Development
- Ileen B. WinickChief People Officer
- Susan StewartChief Regulatory Officer
- William Nichols GarrettChief Medical Officer
- Mark SimsChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela Candel Therapeutics, em USD.
- Cap. de mercado
- 631,3 mi
- Receita (TTM)
- 31 mil
- P/L
- —
- LPA (diluído, TTM)
- -1.5
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -48,3 mi | -38,2 mi | |
| 0 | -33,4 mi | -55,2 mi | |
| 31 mil | -38,4 mi | -37,9 mi | |
| 125 mil | -34,7 mi | -18,8 mi |